Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470262 · ClinicalTrials.gov registry record · NA
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT00470262: Completed NA study, sponsored by VA Office of Research and Development.
NCT00470262 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00470262, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
The relationship between obesity and insulin resistance is known, however the mechanism(s) associating obesity with insulin resistance is not well understood. Inflammation and accumulation of fat in non fat tissue (like muscle) are conditions found on obesity which could be the potential link between obesity and insulin resistance. This study is designed to test the effects of two different drugs on numerous features of the obesity and insulin resistance in subjects with impaired glucose tolerance. Impaired glucose tolerance is a condition where blood sugar is too high after drinking a sugary drink containing 75 grams of sugar. Impaired glucose tolerant subjects are insulin resistant and at risk of developing diabetes. The drugs to be used are fenofibrate and pioglitazone. Fenofibrate is used to reduce the amount of fat (triglycerides) in the blood while pioglitazone is routinely used to make the body more sensitive to insulin in patients with diabetes. The purpose of this study is to compare the effects of either of these two medications (pioglitazone and fenofibrate) alone or the combination of both on fat accumulation in body (muscle) and inflammation. The amount of fat accumulation in muscle is thought to affect insulin sensitivity. In addition, the changes in the level of proteins produced by fat tissues will be studied in response to the two medications in this study. These proteins are thought to be involved in diabetes and insulin resistance. These studies are designed to examine fundamental clinical mechanisms underlying the metabolic syndrome and diabetes.
Interventions
- DRUG Fenofibrate 145mg PO QD
- DRUG Pioglitazone 45 mg PO QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2007-01 |
| Est. Completion | 2014-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470262
The ClinicalTrials.gov registry entry for NCT00470262 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fenofibrate 145mg PO QD is the first listed.
NCT00470262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470262 about?
NCT00470262 is a clinical study titled "Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation". The relationship between obesity and insulin resistance is known, however the mechanism(s) associating obesity with insulin resistance is not well understood. Inflammation and accumulation of fat in non fat tissue (like muscle) are conditions found on obesity which could be the potential link betwee...
What is the current status of trial NCT00470262?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2007-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00470262?
The interventions under investigation include: Fenofibrate 145mg PO QD (DRUG), Pioglitazone 45 mg PO QD (DRUG).
Who is sponsoring clinical trial NCT00470262?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.